Canagliflozin

For type 2 diabetes?

YES NO

improves glycemic control? FDA 2018

reduces the risk of CV complications?
YES NO
weight loss & reduced systolic BP YES NO
with diet and exercise? high blood sugar

YES NO
- the THIRD diabetes drug to receive a CV
ontrolled blood sugar indication and the FIRST oral to receive a
specific major adverse CV events
ineffectivity of desired action indication